Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
599 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
21 Recruiting Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
Condition: Neuroendocrine Tumors
Intervention: Drug: AdVince
22 Recruiting Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumor
Intervention: Other: laboratory biomarker analysis
23 Recruiting Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Metronomic cyclophosphamide;   Drug: Interferon-alpha
24 Recruiting Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
25 Recruiting A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Condition: Neuroendocrine Tumours
26 Recruiting Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Lanreotide (Autogel formulation);   Drug: Placebo
27 Recruiting Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Condition: Neuroendocrine Tumors
Interventions: Drug: Sunitinib;   Drug: Everolimus;   Procedure: Surgery
28 Recruiting Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Condition: Neuroendocrine Tumours
Intervention: Drug: Lanreotide (Autogel formulation) and Temozolomide
29 Recruiting Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours
Condition: Gastrointestinal Neuroendocrine Tumours
30 Not yet recruiting SUV on 68Ga-DOTANOC PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTANOC PET/CT
31 Recruiting A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Condition: Neuroendocrine Tumors Metastatic to the Liver
Intervention: Drug: Rose bengal disodium
32 Recruiting Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
33 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
34 Not yet recruiting Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival
Condition: Pancreatic Neuroendocrine Tumor
Intervention: Procedure: pancreatectomy
35 Not yet recruiting Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Condition: Pancreatic Neuroendocrine Tumors
36 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
37 Recruiting The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: sunitinib
38 Recruiting A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Interventions: Drug: lanreotide;   Drug: Placebo
39 Recruiting Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
40 Not yet recruiting Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib
Condition: Pancreatic Neuroendocrine Tumour Metastatic
Intervention: Drug: Sunitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.